Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Abeona Therapeutics (ABEO) over the last 13 years, with Q3 2025 value amounting to $6.9 million.

  • Abeona Therapeutics' Accumulated Expenses rose 3220.73% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 3220.73%. This contributed to the annual value of $6.3 million for FY2024, which is 581.45% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Accumulated Expenses stood at $6.9 million, which was up 3220.73% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Accumulated Expenses peaked at $6.9 million during Q3 2025, and registered a low of $2.2 million during Q2 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $4.2 million (2023), whereas its average is $4.4 million.
  • Per our database at Business Quant, Abeona Therapeutics' Accumulated Expenses plummeted by 4089.04% in 2021 and then skyrocketed by 14342.47% in 2022.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Accumulated Expenses stood at $5.6 million in 2021, then decreased by 28.54% to $4.0 million in 2022, then soared by 49.96% to $6.0 million in 2023, then rose by 5.81% to $6.3 million in 2024, then grew by 8.76% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $5.5 million for Q2 2025, and $3.9 million during Q1 2025.